Abstract: Aspects of the disclosure relate to methods and compositions useful for in vivo and/or in vitro enzyme profiling. In some embodiments, the disclosure provides methods of in vivo enzymatic processing of exogenous molecules followed by detection of signature molecules as representative of the presence of active enzymes associated with diseases or conditions. In some embodiments, the disclosure provides compositions and in vitro methods for localization of enzymatic activity in a tissue sample.

Abstract: In some aspects, the disclosure provides compositions and methods for detecting and monitoring the activity of proteases in vivo using affinity assays. The disclosure relates, in part, to the discovery that biomarker nanoparticles targeted to the lymph nodes of a subject are useful for the diagnosis and monitoring of certain medical conditions (e.g., metastatic cancer, infection with certain pathogenic agents).

Abstract: The present disclosure relates to methods and products associated with in vitro and in vivo protease activity measurements and enzyme profiling. Some aspects of the present disclosure relate to measuring remotely triggered protease activity. In particular, the disclosure relates to methods of in vivo processing of exogenous molecules followed by detection of signature molecules as representative of the presence or absence of active enzymes associated with disease or conditions. The disclosure also relates to products, kits, and databases for use in the methods of the disclosure.

Abstract: Aspects of the disclosure relate to methods and compositions useful for in vivo and/or in vitro enzyme profiling. In some embodiments, the disclosure provides methods of in vivo enzymatic processing of exogenous molecules followed by detection of signature molecules as representative of the presence of active enzymes associated with diseases or conditions. In some embodiments, the disclosure provides compositions and in vitro methods for localization of enzymatic activity in a tissue sample.

Abstract: In some aspects, the disclosure provides compositions and methods for detecting and monitoring the activity of pro teases in vivo using affinity assays. The disclosure relates, in part, to the discovery that biomarker nanoparticles targeted to the lymph nodes of a subject are useful for the diagnosis and monitoring of certain medical conditions (e.g., metastatic cancer, infection with certain pathogenic agents).

Abstract: The present disclosure relates to methods and products associated with in vitro and in vivo protease activity measurements and enzyme profiling. Some aspects of the present disclosure relate to measuring remotely triggered protease activity. In particular, the disclosure relates to methods of in vivo processing of exogenous molecules followed by detection of signature molecules as representative of the presence or absence of active enzymes associated with disease or conditions. The disclosure also relates to products, kits, and databases for use in the methods of the disclosure.

Abstract: In some aspects, the disclosure relates to compositions and method for detection, classification, and treatment of prostate cancer. In some embodiments, the disclosure relates to prostate protease nanosensors comprising a scaffold linked to a prostate-specific substrate that include a detectable marker capable of being released from the prostate protease nanosensor when exposed to an enzyme present in a prostate. In some embodiments, the disclosure relates to methods of classifying prostate cancer in a subject based upon detection of detectable markers in a sample obtained from a subject who has been administered prostate protease nanosensors.

Abstract: Aspects of the present disclosure relate to methods and compositions useful for in vivo and/or in vitro profiling of proteases present in the lung. In some embodiments, the disclosure provides methods of in vivo enzymatic processing of exogenous molecules followed by detection of detectable markers as representative of the presence of active proteases associated with a lung disease, for example, lung cancer and lung infections. In some embodiments, the disclosure provides compositions and methods for production of a lung disease signature and diagnosis of lung disease.

Abstract: In some aspects, the disclosure relates to compositions and method for detection, classification, and treatment of prostate cancer. In some embodiments, the disclosure relates to prostate protease nanosensors comprising a scaffold linked to a prostate-specific substrate that include a detectable marker capable of being released from the prostate protease nanosensor when exposed to an enzyme present in a prostate. In some embodiments, the disclosure relates to methods of classifying prostate cancer in a subject based upon detection of detectable markers in a sample obtained from a subject who has been administered prostate protease nanosensors.

Abstract: The present disclosure relates to methods and products associated with in vitro and in vivo protease activity measurements and enzyme profiling. Some aspects of the present disclosure relate to measuring remotely triggered protease activity. In particular, the disclosure relates to methods of in vivo processing of exogenous molecules followed by detection of signature molecules as representative of the presence or absence of active enzymes associated with disease or conditions. The disclosure also relates to products, kits, and databases for use in the methods of the disclosure.

Abstract: In some aspects, the disclosure provides compositions and methods for detecting and monitoring the activity of pro teases in vivo using affinity assays. The disclosure relates, in part, to the discovery that biomarker nanoparticles targeted to the lymph nodes of a subject are useful for the diagnosis and monitoring of certain medical conditions (e.g., metastatic cancer, infection with certain pathogenic agents).

Abstract: Aspects of the disclosure relate to methods and compositions useful for in vivo and/or in vitro enzyme profiling. In some embodiments, the disclosure provides methods of in vivo enzymatic processing of exogenous molecules followed by detection of signature molecules as representative of the presence of active enzymes associated with diseases or conditions. In some embodiments, the disclosure provides compositions and in vitro methods for localization of enzymatic activity in a tissue sample.